nach oben

Current Diabetes Reports

Erschienen in:

01.12.2019 | Microvascular Complications—Nephropathy (M Afkarian and B Roshanravan, Section Editors)

Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease

verfasst von: G. Michelle Ducasa, Alla Mitrofanova, Alessia Fornoni

Erschienen in: Current Diabetes Reports | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this review is to review the role that renal parenchymal lipid accumulation plays in contributing to diabetic kidney disease (DKD), specifically contributing to the mitochondrial dysfunction observed in glomerular renal cells in the context of DKD development and progression.

Recent Findings

Mitochondrial dysfunction has been observed in experimental and clinical DKD. Recently, Ayanga et al. demonstrate that podocyte-specific deletion of a protein involved in mitochondrial dynamics protects from DKD progression. Furthermore, our group has recently shown that ATP-binding cassette A1 (a protein involved in cholesterol and phospholipid efflux) is significantly reduced in clinical and experimental DKD and that genetic or pharmacological induction of ABCA1 is sufficient to protect from DKD. ABCA1 deficiency in podocytes leads to mitochondrial dysfunction observed with alterations of mitochondrial lipids, in particular, cardiolipin (a mitochondrial-specific phospholipid). However, through pharmacological reduction of cardiolipin peroxidation DKD progression is reverted.

Summary

Lipid metabolism is significantly altered in the diabetic kidney and renders cellular components, such as the podocyte, susceptible to injury leading to worsened DKD progression. Dysfunction of the lipid metabolism pathway can also lead to mitochondrial dysfunction and mitochondrial lipid alteration. Future research aimed at targeting mitochondrial lipids content and function could prove to be beneficial for the treatment of DKD.

Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51(1 Suppl 1):S1–320.PubMed

Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia. 1999;42(11):1341–4.PubMed

Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342–8.PubMedPubMedCentral

Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007;56(8):2155–60.PubMed

White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes. 2002;51(10):3083–9.PubMed

Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res. 2014;55(3):561–72.PubMedPubMedCentral

Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem. 2005;280(37):32317–25.PubMed

Merscher-Gomez S, Guzman J, Pedigo CE, Lehto M, Aguillon-Prada R, Mendez A, et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes. 2013;62(11):3817–27.PubMedPubMedCentral

Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 2005;54(8):2328–35.PubMed

10.

Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes. 2006;55(9):2502–9.PubMed

11.

Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol. 2009;297(6):F1587–96.PubMedPubMedCentral

12.

Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal. 2010;12(4):537–77.PubMedPubMedCentral

13.

Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291–312.PubMed

14.

Kampe K, Sieber J, Orellana JM, Mundel P, Jehle AW. Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on acetyl-CoA carboxylases 1 and 2. Am J Physiol Renal Physiol. 2014;306(4):F401–9.PubMed

15.

Sieber J, Weins A, Kampe K, Gruber S, Lindenmeyer MT, Cohen CD, et al. Susceptibility of podocytes to palmitic acid is regulated by Stearoyl-CoA desaturases 1 and 2. Am J Pathol. 2013;183(3):735–44.PubMedPubMedCentral

16.

Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24(11):1901–12.PubMedPubMedCentral

17.

Qi H, Casalena G, Shi S, Yu L, Ebefors K, Sun Y, et al. Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. Diabetes. 2017;66(3):763–78.PubMed

18.

Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes Ther. 2016;7(2):203–19.PubMedPubMedCentral

19.

Lara-Castro C, Garvey WT. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol Metab Clin N Am. 2008;37(4):841–56.

20.

Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84–91.PubMedPubMedCentral

21.

•• Ducasa GM, Mitrofanova A, Mallela SK, Liu X, Molina J, Sloan A, et al. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. J Clin Invest. 2019;129(8):3387–400. Findings from this study suggest that decreased expression of ABCA1 plays a pivotal role in alteration in the OXPHOS complexes and is associated with cardiolipin accumulation. PubMedPubMedCentral

22.

Zhou C, Pridgen B, King N, Xu J, Breslow JL. Hyperglycemic Ins2AkitaLdlr⁻/⁻ mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease. J Lipid Res. 2011;52(8):1483–93.PubMedPubMedCentral

23.

Jun JY, Ma Z, Segar L. Spontaneously diabetic Ins2(+/Akita):apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis. Am J Physiol Endocrinol Metab. 2011;301(1):E145–54.PubMedPubMedCentral

24.

Van Krieken R, Marway M, Parthasarathy P, Mehta N, Ingram AJ, Gao B, et al. Inhibition of SREBP with Fatostatin does not attenuate early diabetic nephropathy in male mice. Endocrinology. 2018;159(3):1479–95.PubMed

25.

Mitrofanova A, Molina J, Varona Santos J, Guzman J, Morales XA, Ducasa GM, et al. Hydroxypropyl-beta-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Kidney Int. 2018;94(6):1151–9.PubMedPubMedCentral

26.

Masereeuw R, Russel FG. Regulatory pathways for ATP-binding cassette transport proteins in kidney proximal tubules. AAPS J. 2012;14(4):883–94.PubMedPubMedCentral

27.

Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 2008;73(2):220–5.PubMed

28.

Huls M, van den Heuvel JJ, Dijkman HB, Russel FG, Masereeuw R. ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney. Kidney Int. 2006;69(12):2186–93.PubMed

29.

Mahringer A, Bernd A, Miller DS, Fricker G. Aryl hydrocarbon receptor ligands increase ABC transporter activity and protein expression in killifish (Fundulus heteroclitus) renal proximal tubules. Biol Chem. 2019;400(10):1335–45.PubMed

30.

Choi HJ, Cho HY, Ro H, Lee SH, Han KH, Lee H, et al. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr Nephrol. 2011;26(11):1981–8.PubMed

31.

Ganda A, Yvan-Charvet L, Zhang Y, Lai EJ, Regunathan-Shenk R, Hussain FN, et al. Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD. J Mol Cell Cardiol. 2017;112:114–22.PubMedPubMedCentral

32.

Ibold B, Faust I, Tiemann J, Gorgels T, Bergen AAB, Knabbe C, et al. Abcc6 deficiency in mice leads to altered ABC transporter gene expression in metabolic active tissues. Lipids Health Dis. 2019;18(1):2.PubMedPubMedCentral

33.

Tang C, Kanter JE, Bornfeldt KE, Leboeuf RC, Oram JF. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res. 2010;51(7):1719–28.PubMedPubMedCentral

34.

Pedigo CE, Ducasa GM, Leclercq F, Sloan A, Mitrofanova A, Hashmi T, et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J Clin Invest. 2016;126(9):3336–50.PubMedPubMedCentral

35.

Ferrans VJ, Fredrickson DS. The pathology of Tangier disease. A light and electron microscopic study. Am J Pathol. 1975;78(1):101–58.PubMedPubMedCentral

36.

Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 2014;55(3):561–72.PubMed

37.

Russo GT, De Cosmo S, Viazzi F, Pacilli A, Ceriello A, Genovese S, et al. Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD Annals Initiative. Diabetes Care. 2016;39(12):2278–87.PubMed

38.

Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158(9):998–1004.PubMed

39.

Cusick M, Chew EY, Hoogwerf B, Agron E, Wu L, Lindley A, et al. Risk factors for renal replacement therapy in the early treatment diabetic retinopathy study (ETDRS), early treatment diabetic retinopathy study report no. 26. Kidney Int. 2004;66(3):1173–9.PubMed

40.

Wei P, Grimm PR, Settles DC, Balwanz CR, Padanilam BJ, Sansom SC. Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus. Ren Fail. 2009;31(6):503–13.PubMed

41.

Lu L, Peng WH, Wang W, Wang LJ, Chen QJ, Shen WF. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats. J Zhejiang Univ Sci B. 2011;12(8):652–9.PubMedPubMedCentral

42.

Sun H, Yuan Y, Sun ZL. Cholesterol contributes to diabetic nephropathy through SCAP-SREBP-2 pathway. Int J Endocrinol. 2013;2013:592576.PubMedPubMedCentral

43.

Wang L, Yao X, Li Q, Sun S. Effect of simvastatin on lipid accumulation and the expression of CXCL16 and nephrin in podocyte induced by oxidized LDL. J Invest Surg. 2018;31(2):69–74.PubMed

44.

Su W, Cao R, He YC, Guan YF, Ruan XZ. Crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease. Kidney Dis (Basel). 2017;3(4):171–80.

45.

Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5(12):713–21.PubMed

46.

Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes. 2010;59(11):2916–27.PubMedPubMedCentral

47.

Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L, et al. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol. 2015;52(6):1045–56.PubMed

48.

Zhang Y, Ma KL. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Am J Physiol Endocrinol Metab. 2015;308(12):E1140–8.PubMed

49.

Yang Y, Yang Q, Yang J, Ma Y, Ding G. Angiotensin II induces cholesterol accumulation and injury in podocytes. Sci Rep. 2017;7(1):10672.PubMedPubMedCentral

50.

Hu J, Yang Q, Chen Z, Liang W, Feng J, Ding G. Small GTPase Arf6 regulates diabetes-induced cholesterol accumulation in podocytes. J Cell Physiol. 2019;234(12):23559–70.PubMed

51.

Simon N, Hertig A. Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis. Front Med (Lausanne). 2015;2:52.

52.

Sieber J, Jehle AW. Free fatty acids and their metabolism affect function and survival of podocytes. Front Endocrinol. 2014;5:186.

53.

Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108(6):785–91.PubMedPubMedCentral

54.

Han J, Hajjar DP, Febbraio M, Nicholson AC. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem. 1997;272(34):21654–9.PubMed

55.

Nassir F, Wilson B, Han X, Gross RW, Abumrad NA. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol Chem. 2007;282(27):19493–501.PubMed

56.

Hua W, Huang HZ, Tan LT, Wan JM, Gui HB, Zhao L, et al. CD36 mediated fatty acid-induced Podocyte apoptosis via oxidative stress. PLoS One. 2015;10(5):e0127507.PubMedPubMedCentral

57.

Hou Y, Wu M, Wei J, Ren Y, Du C, Wu H, et al. CD36 is involved in high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells. Biochem Biophys Res Commun. 2015;468(1–2):281–6.PubMed

58.

Zhao J, Rui HL, Yang M, Sun LJ, Dong HR, Cheng H. CD36-mediated lipid accumulation and activation of NLRP3 inflammasome lead to podocyte injury in obesity-related glomerulopathy. Mediat Inflamm. 2019;2019:3172647.

59.

Feng L, Gu C, Li Y, Huang J. High glucose promotes CD36 expression by upregulating peroxisome proliferator-activated receptor gamma levels to exacerbate lipid deposition in renal tubular cells. Biomed Res Int. 2017;2017:1414070.PubMedPubMedCentral

60.

Ding W, Yousefi K, Goncalves S, Goldstein BJ, Sabater AL, Kloosterboer A, et al. Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight. 2018;3(6).

61.

Yang X, Wu Y, Li Q, Zhang G, Wang M, Yang H, et al. CD36 promotes Podocyte apoptosis by activating the Pyrin domain-containing-3 (NLRP3) inflammasome in primary nephrotic syndrome. Med Sci Monit. 2018;24:6832–9.PubMedPubMedCentral

62.

Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21(1):37–46.PubMed

63.

Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084–8.PubMedPubMedCentral

64.

Merscher S, Fornoni A. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol. 2014;5:127.

65.

Di Pardo A, Basit A, Armirotti A, Amico E, Castaldo S, Pepe G, et al. De novo synthesis of sphingolipids is defective in experimental models of Huntington's disease. Front Neurosci. 2017;11:698.PubMedPubMedCentral

66.

Motyl J, Przykaza L, Boguszewski PM, Kosson P, Strosznajder JB. Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology. 2018;135:139–50.PubMed

67.

Joly S, Dalkara D, Pernet V. Sphingosine 1-phosphate receptor 1 modulates CNTF-induced axonal growth and neuroprotection in the mouse visual system. Neural Plast. 2017;2017:6818970.PubMedPubMedCentral

68.

Choi HS, Kim KH. Decreased expression of Sphingosine-1-Phosphate Receptor 1 in the blood leukocyte of rheumatoid arthritis patients. Immune Netw. 2018;18(5):e39.PubMedPubMedCentral

69.

Bhat VK, Bernhart E, Plastira I, Fan K, Tabrizi-Wizsy NG, Wadsack C, et al. Pharmacological inhibition of serine palmitoyl transferase and sphingosine kinase-1/-2 inhibits Merkel cell carcinoma cell proliferation. J Invest Dermatol 2019;139(4):807–17.

70.

Zheng X, Li W, Ren L, Liu J, Pang X, Chen X, et al. The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: potential target for anticancer therapy. Pharmacol Ther 2019;195:85–99.

71.

Nagahashi M, Abe M, Sakimura K, Takabe K, Wakai T. The role of sphingosine-1-phosphate in inflammation and cancer progression. Cancer Sci. 2018;109(12):3671–8.PubMedPubMedCentral

72.

El Buri A, Adams DR, Smith D, Tate RJ, Mullin M, Pyne S, et al. The sphingosine 1-phosphate receptor 2 is shed in exosomes from breast cancer cells and is N-terminally processed to a short constitutively active form that promotes extracellular signal regulated kinase activation and DNA synthesis in fibroblasts. Oncotarget. 2018;9(50):29453–67.PubMedPubMedCentral

73.

Ahmad A, Mitrofanova A, Bielawski J, Yang Y, Marples B, Fornoni A, et al. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes. FASEB J. 2017;31(2):771–80.PubMed

74.

Bajwa A, Huang L, Kurmaeva E, Ye H, Dondeti KR, Chroscicki P, et al. Sphingosine kinase 2 deficiency attenuates kidney fibrosis via IFN-gamma. Journal of the American Society of Nephrology : JASN. 2017;28(4):1145–61.PubMed

75.

Perry HM, Huang L, Ye H, Liu C, Sung SJ, Lynch KR, et al. Endothelial sphingosine 1-phosphate receptor-1 mediates protection and recovery from acute kidney injury. J Am Soc Nephrol. 2016;27(11):3383–93.PubMedPubMedCentral

76.

Prasad R, Hadjidemetriou I, Maharaj A, Meimaridou E, Buonocore F, Saleem M, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest. 2017;127(3):942–53.PubMedPubMedCentral

77.

Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes. 2006;55(9):2579–87.PubMed

78.

Kowalski GM, Carey AL, Selathurai A, Kingwell BA, Bruce CR. Plasma sphingosine-1-phosphate is elevated in obesity. PLoS One. 2013;8(9):e72449.PubMedPubMedCentral

79.

Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res. 2011;52(3):509–17.PubMedPubMedCentral

80.

Rapizzi E, Taddei ML, Fiaschi T, Donati C, Bruni P, Chiarugi P. Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor. Cell Mol Life Sci. 2009;66(19):3207–18.PubMed

81.

Jun DJ, Lee JH, Choi BH, Koh TK, Ha DC, Jeong MW, et al. Sphingosine-1-phosphate modulates both lipolysis and leptin production in differentiated rat white adipocytes. Endocrinology. 2006;147(12):5835–44.PubMed

82.

Bruce CR, Risis S, Babb JR, Yang C, Kowalski GM, Selathurai A, et al. Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice. Diabetes. 2012;61(12):3148–55.PubMedPubMedCentral

83.

Bruce CR, Risis S, Babb JR, Yang C, Lee-Young RS, Henstridge DC, et al. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice. Endocrinology. 2013;154(1):65–76.PubMed

84.

Osawa Y, Uchinami H, Bielawski J, Schwabe RF, Hannun YA, Brenner DA. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem. 2005;280(30):27879–87.PubMed

85.

Liu Y, Saiyan S, Men TY, Gao HY, Wen C, Liu Y, et al. Hepatopoietin Cn reduces ethanol-induced hepatoxicity via sphingosine kinase 1 and sphingosine 1-phosphate receptors. J Pathol. 2013;230(4):365–76.PubMed

86.

Lee SY, Hong IK, Kim BR, Shim SM, Sung Lee J, Lee HY, et al. Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice. Hepatology. 2015;62(1):135–46.PubMed

87.

Nojiri T, Kurano M, Tokuhara Y, Ohkubo S, Hara M, Ikeda H, et al. Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice. J Diabetes Investig. 2014;5(6):639–48.PubMedPubMedCentral

88.

Lovric S, Goncalves S, Gee HY, Oskouian B, Srinivas H, Choi WI, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 2017;127(3):912–28.PubMedPubMedCentral

89.

Linhares ND, Arantes RR, Araujo SA, Pena SDJ. Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1. Clin Kidney J. 2018;11(4):462–7.PubMed

90.

Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR, et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int. 2011;79(10):1090–8.PubMedPubMedCentral

91.

Chalfant CE, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci. 2005;118(Pt 20):4605–12.PubMed

92.

Gómez-Muñoz A, Gangoiti P, Granado MH, Arana L, Ouro A. Ceramide 1-phosphate in cell survival and inflammatory signaling. In: Chalfant CE, Poeta M, editors. Shingolipids as signaling and regulatory molecules. Austin: Landes Bioscience. 2000-2013. p.

93.

Gomez-Munoz A. Ceramide 1-phosphate/ceramide, a switch between life and death. Biochim Biophys Acta. 2006;1758(12):2049–56.PubMed

94.

Hait NC, Maiti A. The role of sphingosine-1-phosphate and ceramide-1-phosphate in inflammation and cancer. Mediators Inflamm. 2017;2017:4806541. https://doi.org/10.1155/2017/4806541.CrossRefPubMedPubMedCentral

95.

Kim CH, Wu W, Wysoczynski M, Abdel-Latif A, Sunkara M, Morris A, et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia. 2012;26(1):106–16.PubMed

96.

Pastukhov O, Schwalm S, Romer I, Zangemeister-Wittke U, Pfeilschifter J, Huwiler A. Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts. Cell Physiol Biochem. 2014;34(1):119–33.PubMed

97.

Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 2014;20(4):687–95.PubMed

98.

Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.PubMedPubMedCentral

99.

Heinz LX, Baumann CL, Koberlin MS, Snijder B, Gawish R, Shui G, et al. The lipid-modifying enzyme SMPDL3B negatively regulates innate immunity. Cell Rep. 2015;11(12):1919–28.PubMedPubMedCentral

100.

Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015;26(1):133–47.PubMed

101.

• Mitrofanova A, Mallela SK, Ducasa GM, Yoo TH, Rosenfeld-Gur E, Zelnik ID, et al. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease. Nat Commun. 2019;10(1):2692. Findings from this study suggest that sphingolipid SMPDL3b is a modulator of insulin signaling in podocytes. Excess of SMPDL3b in human podocytes results in decreased C1P content contributing to DKD progression. PubMedPubMedCentral

102.

Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57(6):1446–54.PubMed

103.

Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225–33.PubMed

104.

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–20.PubMed

105.

Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A. 2000;97(22):12222–6.PubMedPubMedCentral

106.

Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787–90.PubMed

107.

Small DM, Bennett NC, Roy S, Gabrielli BG, Johnson DW, Gobe GC. Oxidative stress and cell senescence combine to cause maximal renal tubular epithelial cell dysfunction and loss in an in vitro model of kidney disease. Nephron Exp Nephrol. 2012;122(3–4):123–30.PubMed

108.

Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A. 2006;103(8):2653–8.PubMedPubMedCentral

109.

Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11(12):872–84.PubMed

110.

van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. Cold Spring Harb Perspect Biol. 2013;5(6).

111.

Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes. 2008;57(3):714–23.PubMed

112.

Ayanga BA, Badal SS, Wang Y, Galvan DL, Chang BH, Schumacker PT, et al. Dynamin-related protein 1 deficiency improves mitochondrial fitness and protects against progression of diabetic nephropathy. J Am Soc Nephrol. 2016;27(9):2733–47.PubMedPubMedCentral

113.

Qin X, Zhao Y, Gong J, Huang W, Su H, Yuan F, et al. Berberine protects glomerular podocytes via inhibiting Drp1-mediated mitochondrial fission and dysfunction. Theranostics. 2019;9(6):1698–713.PubMedPubMedCentral

114.

Lee WC, Chiu CH, Chen JB, Chen CH, Chang HW. Mitochondrial fission increases apoptosis and decreases autophagy in renal proximal tubular epithelial cells treated with high glucose. DNA Cell Biol. 2016;35(11):657–65.PubMed

115.

Bischof J, Salzmann M, Streubel MK, Hasek J, Geltinger F, Duschl J, et al. Clearing the outer mitochondrial membrane from harmful proteins via lipid droplets. Cell Death Discov. 2017;3:17016.PubMedPubMedCentral

116.

Dudkina NV, Kouril R, Peters K, Braun HP, Boekema EJ. Structure and function of mitochondrial supercomplexes. Biochim Biophys Acta. 2010;1797(6–7):664–70.PubMed

117.

Gredilla R, Phaneuf S, Selman C, Kendaiah S, Leeuwenburgh C, Barja G. Short-term caloric restriction and sites of oxygen radical generation in kidney and skeletal muscle mitochondria. Ann N Y Acad Sci. 2004;1019:333–42.PubMed

118.

Han D, Williams E, Cadenas E. Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. Biochem J. 2001;353(Pt 2):411–6.PubMedPubMedCentral

119.

St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem. 2002;277(47):44784–90.PubMed

120.

Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol. 2005;289(2):F420–30.PubMed

121.

Horvath SE, Daum G. Lipids of mitochondria. Prog Lipid Res. 2013;52(4):590–614.PubMed

122.

Hasan SS, Yamashita E, Ryan CM, Whitelegge JP, Cramer WA. Conservation of lipid functions in cytochrome bc complexes. J Mol Biol. 2011;414(1):145–62.PubMedPubMedCentral

123.

Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012;26(6):711–23.PubMedPubMedCentral

124.

Bottinger L, Horvath SE, Kleinschroth T, Hunte C, Daum G, Pfanner N, et al. Phosphatidylethanolamine and cardiolipin differentially affect the stability of mitochondrial respiratory chain supercomplexes. J Mol Biol. 2012;423(5):677–86.PubMed

125.

Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochim Biophys Acta. 2014;1837(4):408–17.PubMed

126.

Kutik S, Rissler M, Guan XL, Guiard B, Shui G, Gebert N, et al. The translocator maintenance protein Tam41 is required for mitochondrial cardiolipin biosynthesis. J Cell Biol. 2008;183(7):1213–21.PubMedPubMedCentral

127.

Zhang M, Mileykovskaya E, Dowhan W. Cardiolipin is essential for organization of complexes III and IV into a supercomplex in intact yeast mitochondria. J Biol Chem. 2005;280(33):29403–8.PubMed

128.

Mileykovskaya E, Penczek PA, Fang J, Mallampalli VK, Sparagna GC, Dowhan W. Arrangement of the respiratory chain complexes in Saccharomyces cerevisiae supercomplex III2IV2 revealed by single particle cryo-electron microscopy. J Biol Chem. 2012;287(27):23095–103.PubMedPubMedCentral

129.

Fobker M, Voss R, Reinecke H, Crone C, Assmann G, Walter M. Accumulation of cardiolipin and lysocardiolipin in fibroblasts from Tangier disease subjects. FEBS Lett. 2001;500(3):157–62.PubMed

130.

Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22(4):336–45.PubMed

131.

Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22(4):347–51.PubMed

132.

Joshi AS, Zhou J, Gohil VM, Chen S, Greenberg ML. Cellular functions of cardiolipin in yeast. Biochim Biophys Acta. 2009;1793(1):212–8.PubMed

133.

Claypool SM, Koehler CM. The complexity of cardiolipin in health and disease. Trends Biochem Sci. 2012;37(1):32–41.PubMed

134.

Osman C, Voelker DR, Langer T. Making heads or tails of phospholipids in mitochondria. J Cell Biol. 2011;192(1):7–16.PubMedPubMedCentral

135.

Gonzalvez F, Schug ZT, Houtkooper RH, MacKenzie ED, Brooks DG, Wanders RJ, et al. Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. J Cell Biol. 2008;183(4):681–96.PubMedPubMedCentral

136.

Bayir H, Fadeel B, Palladino MJ, Witasp E, Kurnikov IV, Tyurina YY, et al. Apoptotic interactions of cytochrome c: redox flirting with anionic phospholipids within and outside of mitochondria. Biochim Biophys Acta. 2006;1757(5–6):648–59.PubMed

137.

Schug ZT, Gottlieb E. Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. Biochim Biophys Acta. 2009;1788(10):2022–31.PubMed

138.

Lutter M, Fang M, Luo X, Nishijima M, Xie X, Wang X. Cardiolipin provides specificity for targeting of tBid to mitochondria. Nat Cell Biol. 2000;2(10):754–61.PubMed

139.

Youle RJ, Karbowski M. Mitochondrial fission in apoptosis. Nat Rev Mol Cell Biol. 2005;6(8):657–63.PubMed

140.

de Kroon AI, Dolis D, Mayer A, Lill R, de Kruijff B. Phospholipid composition of highly purified mitochondrial outer membranes of rat liver and Neurospora crassa. Is cardiolipin present in the mitochondrial outer membrane? Biochim Biophys Acta. 1997;1325(1):108–16.PubMed

141.

Zinser E, Daum G. Isolation and biochemical characterization of organelles from the yeast, Saccharomyces cerevisiae. Yeast. 1995;11(6):493–536.PubMed

142.

Ribas V, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondria, cholesterol and cancer cell metabolism. Clin Transl Med. 2016;5(1):22.PubMedPubMedCentral

143.

Unsay JD, Cosentino K, Subburaj Y, Garcia-Saez AJ. Cardiolipin effects on membrane structure and dynamics. Langmuir. 2013;29(51):15878–87.PubMed

144.

Arnarez C, Marrink SJ, Periole X. Identification of cardiolipin binding sites on cytochrome c oxidase at the entrance of proton channels. Sci Rep. 2013;3:1263.PubMedPubMedCentral

145.

Arnarez C, Mazat JP, Elezgaray J, Marrink SJ, Periole X. Evidence for cardiolipin binding sites on the membrane-exposed surface of the cytochrome bc1. J Am Chem Soc. 2013;135(8):3112–20.PubMed

146.

McKenzie M, Lazarou M, Thorburn DR, Ryan MT. Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. J Mol Biol. 2006;361(3):462–9.PubMed

147.

Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–50.PubMedPubMedCentral

148.

Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017–28.PubMedPubMedCentral

149.

Szeto HH, Liu S, Soong Y, Alam N, Prusky GT, Seshan SV. Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury. Kidney Int. 2016;90(5):997–1011.PubMed

Titel: Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease
verfasst von: G. Michelle Ducasa
Alla Mitrofanova
Alessia Fornoni
Publikationsdatum: 01.12.2019
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 12/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1263-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

The Effects of Lifestyle and/or Vitamin D Supplementation Interventions on Pregnancy Outcomes: What Have We Learned from the DALI Studies?

Organoids from the Human Fetal and Adult Pancreas

Academic Detailing in the New Era of Diabetes Medication Management

Brain Stimulation to Modulate Food Intake and Eating Behavior

Natural Alternative Sweeteners and Diabetes Management